Our Technology
PLGA microspheres are not new, in fact they have been commercially available for nearly 40 years, with 16 drug approvals. One challenge PLGA microspheres have faced is a lack of uniformity. A potential consequence of non-uniform particles is batch-to-batch variation in drug release profiles, causing phenomena such as burst release.
The Problem
Imperfect Particles
The Problem
Imperfect Particles
PLGA microspheres are not new, in fact they have been commercially available for nearly 40 years, with 16 drug approvals. One challenge PLGA microspheres have faced is a lack of uniformity. A potential consequence of non-uniform particles is batch-to-batch variation in drug release profiles, causing phenomena such as burst release.
Faros™ has solved the problem of batch-to-batch variation with spherical, non-porous particles that deliver consistent drug release profiles for patients. The micro-size of the Faros™ technology, smaller than red blood cells, enables injections through very small gauge needles that can minimize injection site pain, and has potential to improve the safety of soft tissue injections and aerodynamic properties compatible with inhalation applications. Additionally, the technology is surfactant and preservative free to reduce the potential for adverse effects.
The Solution
Faros™ Precision Particles
The Solution
Faros™ Precision Particles
Faros™ has solved the problem of batch-to-batch variation with spherical, non-porous particles that deliver consistent drug release profiles for patients. The micro-size of the Faros™ technology, smaller than red blood cells, enables injections through very small gauge needles that can minimize injection site pain, and has potential to improve the safety of soft tissue injections and aerodynamic properties compatible with inhalation applications. Additionally, the technology is surfactant and preservative free to reduce the potential for adverse effects.
